The synergistic inhibition of breast cancer proliferation by combined treatment with 4EGI-1 and MK2206 |
| |
Authors: | Hongtao Wang Fang Huang Jian Wang Peng Wang Wenjie Lv Liu Hong Shanhu Li Jianguang Zhou |
| |
Institution: | 1.Laboratory of Medical Molecular Biology; Beijing Institute of Biotechnology; Beijing, P.R. China;2.State Key Laboratory of Experimental Hematology Institute of Hematology and Blood Diseases Hospital; Chinese Academy of Medical Sciences & Peking Union Medical College; Tianjin, P.R. China |
| |
Abstract: | Cap-dependent translation is a potential cancer-related target (oncotarget) due to its critical role in cancer initiation and progression. 4EGI-1, an inhibitor of eIF4E/eIF4G interaction, was discovered by screening chemical libraries of small molecules. 4EGI-1 inhibits cap-dependent translation initiation by impairing the assembly of the eIF4E/eIF4G complex, and therefore is a potential anti-cancer agent. Here, we report that 4EGI-1 also inhibits mTORC1 signaling independent of its inhibitory role on cap-dependent translation initiation. The inhibition of mTORC1 signaling by 4EGI-1 activates Akt due to both abrogation of the negative feedback loops from mTORC1 to PI3K and activation of mTORC2. We further validated that mTORC2 activity is required for 4EGI-1-mediated Akt activation. The activated Akt counteracted the anticancer effects of 4EGI-1. In support of this model, inhibition of Akt potentiates the antitumor activity of 4EGI-1 both in vitro and in a xenograft mouse model in vivo. Our results suggest that a combination of 4EGI-1and Akt inhibitor is a rational approach for the treatment of cancer. |
| |
Keywords: | AKT eIF4E eIF4F complex cap-dependent translation 4EBP1 4EGI-1 mTORC1 mTORC2 |
|